On MAY 7, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported financial results for the three months ended March 31, 2014. For the first quarter of 2014, the Company reported a net loss of $16.1 million or $0.17 per share, compared with a net loss of $11.7 million or $0.14 per share for the first quarter of 2013. Cash, cash equivalents, marketable securities and interest receivable as of March 31, 2014 were $144.7 million. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on last trading day company shares ended up $2.70. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) distance from 50-day simple moving average (SMA50) is -12.71%.
DARA BioSciences, Inc. (NASDAQ:IMMY) an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, announced that the Company has implemented its new “No Coupon, No Co-pay, No Hassles” retail patient saving program in support of its flagship products, Gelclair and Soltamox. DARA Biosciences Inc (NASDAQ:DARA) shares fell -10.41% in last trading session and ended the day on $1.12. DARA Gross Margin is 50.00% and its return on assets is -107.20%. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) quarterly performance is -56.08%.
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced its attendance and physicians’ presentations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress in Boston. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) shares moved down -10.00% in last trading session and was closed at $5.58, while trading in range of $5.38 – $6.15. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) year to date (YTD) performance is 66.07%.
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2014 Healthcare Conference on Thursday, May 15, 2014 at 8:00 a.m. Pacific Time in Las Vegas, NV. Mr. Buchi will provide an overview of the Company and its corporate activities. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) ended the last trading day at $5.55. Company weekly volatility is calculated as 8.68% and price to cash ratio as 45.80. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) showed a negative weekly performance of -2.29%.
Leave a Reply